Latest news, press releases, and SEC filings for Sanofi SA (SNYNF) https://caymanjournal.com/stock/SNYNF en-us Copyright 2026, Cayman Journal editorial@caymanjournal.com (Editorial Team) webmaster@caymanjournal.com (Web Master) Mon, 27 Apr 2026 20:21:28 GMT 60 https://caymanjournal.com/logo.png https://caymanjournal.com 144 144 # 🔥 The Headline: A Strong Start to 2026 Sanofi kicked off 2026 with a powerful quarter, posting **double-digit growth** in both sales and its key profit metric. This performance signals that the company's strategy—focusing on new specialty drugs and vaccines—is firing on all cylinders. # 💊 What https://caymanjournal.com/stock/SNYNF/sec-filing/0001121404-26-000004 https://caymanjournal.com/stock/SNYNF/sec-filing/0001121404-26-000004 Thu, 23 Apr 2026 00:00:00 GMT SEC Filing # 🧾 What This Document Is This is a **6-K filing** from Sanofi, a French pharmaceutical giant. Think of it as a "news report" the company must submit to the SEC to update investors on major recent events. This specific filing is a bundle of four separate press releases, all announcing important reg https://caymanjournal.com/stock/SNYNF/sec-filing/0001193125-26-133806 https://caymanjournal.com/stock/SNYNF/sec-filing/0001193125-26-133806 Tue, 31 Mar 2026 00:00:00 GMT SEC Filing